sur GENSIGHT BIOLOGICS S.A. (EPA:SIGHT)
GenSight Biologics: Financial Update and Progress on AAC
On April 7, 2026, GenSight Biologics disclosed its cash position and revenues obtained through its Compassionate Access Authorization (CAA) program as of March 31, 2026. The company had €3.2 million in cash, compared to €2.4 million in December 2025, notably thanks to a €1.7 million equity fundraising.
The AAC program generated €2.6 million in revenue in March 2026, with a treatment cost of €425,000 per injection. GenSight expects the revenue from these programs to cover its annual operating expenses, excluding the costs of a new clinical trial. Several treatments are planned for April, as well as the launch of a program in Israel in the second quarter of 2026.
R. P.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de GENSIGHT BIOLOGICS S.A.